Live Breaking News & Updates on Drug Administration On Biogen Inc

Jul 29, 2021
Top researchers who advised the U.S. Food and Drug Administration on Biogen Inc.’s Alzheimer’s drug blasted the agency for approving it, calling the decision a “regulatory failure” that is “at odds with the evidence.”
The New England Journal of Medicine opinion piece, signed by seven members of an advisory panel that opposed clearing Biogen’s Aduhelm, is another sign of persistent furor over the agency’s decision. Two committees of the House of Representatives investigating the approval have asked the Cambridge, Massachusetts-based biotech to turn over documents about the drug’s development and approval.
Doctors and patients are desperate for new treatments for Alzheimer’s disease, which afflicts more than 5 million Americans. While many researchers have backed the FDA’s move, the drug hasn’t been shown to slow cognitive decline, as two big trials sponsored by Biogen yielded contradictory results. Three of the panel members ....

United States , United Kingdom , San Francisco , Gil Rabinovici , Janet Woodcock , Al Sandrock , Samit Hirawat , Caleb Alexander , University Of California , Japan Eisai Co , Alzheimer Association , Johns Hopkins Bloomberg School Of Public Health , Harvard Medical School , Bristol Myers Squibb Co , Drug Administration On Biogen Inc , Drug Administration , New England Journal , Mayo Clinic , Johns Hopkins Bloomberg School , Public Health , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , சான் பிரான்சிஸ்கோ , ஜேனட் மரக்கட்டை , அல் சாண்ட்ராக் , சமித் ஹிராவத் ,